Steve Krognes

Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Guardant Health, Gritstone bio, Inc. and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc. Mr. Krognes has close to 30 years of life sciences leadership experience and before becoming a board member of Denali Therapeutics, served as its founding chief financial officer. In this role, he led the company’s IPO efforts and built the corporate finance, information technology and site organizations to enable the company to reach a greater scale.

Prior to Denali, Mr. Krognes worked at Genentech and Roche for twelve years. At Genentech, he served as the CFO and as a member of the Executive Committee for six years, where he was responsible for finance, site services and IT. Steve also represented Genentech on the Board and Executive Committee of the California Life Science Association and served as Chairman of the Genentech Access to Care Foundation.

At Roche in Switzerland, Mr. Krognes led the global Mergers & Acquisition team for more than five years. Under Steve’s leadership, the M&A team executed more than 30 transactions worldwide, including the acquisitions of Ventana Medical Systems and Genentech. Steve worked as an investment banker at Goldman Sachs in London, a management consultant at McKinsey in London, and as a venture capitalist in Stockholm.

Steve holds an M.B.A. from Harvard Business School, a B.S. in economics from the Wharton School of the University of Pennsylvania and is a Second Lieutenant in the Royal Norwegian Air Force.